Tricia Rodriguez, Truveta senior applied research scientist & lead study author, explains the study findings concerning why ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

As millions of Americans experience the benefits of weight loss through the use of GLP-1 medications, some orthopedic experts are still torn on the potential effects the medications will have for ...

Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...

While the company is prioritizing RJVA-001 and a lead program in obesity, it's pausing some R&D efforts and laying off 17 percent of its workforce.

More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

The flu big hit the Winthrop High School girls hockey team last week, but Coach Butch Martucci’s determined crew battled through it and eked out a 3-2 victory over Winchester Saturday at the O’Brien ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...